mfn-ext-nq
-
14 Oct, 2025Synligt tumörupptag och rekommenderad doshöjning i Spago Nanomedicals fas I/IIa-studie Tumorad-01
-
14 Oct, 2025Visible tumor uptake and recommended dose increase in Spago Nanomedicals’s Phase I/IIa study Tumorad-01
-
3 Jun, 2025Spago Nanomedical continues patient recruitment in the phase I/IIa study Tumorad-01 as planned after DMC recommendation
-
3 Jun, 2025Spago Nanomedical fortsätter planenligt patientrekryteringen i fas I/IIa-studien Tumorad-01 efter DMC-rekommendation